Ubenimex, an oral dual-inhibitor developed by Eiger BioPharmaceuticals, has failed to demonstrate its effectiveness to treat pulmonary arterial hypertension (PAH) in the Phase 2 LIBERTY study. Initiated in 2016, the LIBERTY trial (NCT02664558) included 61 patients with diagnosed WHO Group 1 PAH across 45 clinical sites in…

Patient enrollment is complete in a Phase 2 clinical trial of ubenimex as an add-on to standard therapy for pulmonary arterial hypertension (PAH), according to ubenimex’s developer, Eiger BioPharmaceuticals. Sixty-one patients at 45 sites in the United States and Canada have been enrolled in the LIBERTY trial (NCT02664558). The randomized, double-blind,…

Eiger BioPharmaceuticals recently announced that a first patient has completed the 24-week dosing in the Phase 2 LIBERTY study assessing ubenimex as a therapy for pulmonary arterial hypertension (PAH). That patient is now continuing with treatment in an open-label extension trial. “There has been tremendous enthusiasm in the entire community — patients, families,…

Eiger BioPharmaceuticals recently reported the dosing of a first patient in its Phase 2 LIBERTY clinical trial, evaluating the effects of ubenimex (Bestatin) as an add-on therapy to current standard of care in patients with pulmonary arterial hypertension (PAH). The study is currently recruiting adult patients with PAH WHO…

Eiger BioPharmaceuticals, Inc. recently announced in a press release that a Notice of Allowance from the United States Patent and Trademark Office (USPTO) has been issued for the U.S. patent application 13/829,321, titled “Treatment of Pulmonary Hypertension with Leukotriene Inhibitors” covering Bestatin™ (ubenimex), a leukotriene A4hydrolase (LTA4H) inhibitor, for treating…

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that focuses on the development and commercialization of drugs for the treatment of rare diseases and conditions with ineffective treatments, announced that ubenimex, a drug developed as a pulmonary arterial hypertension (PAH) therapy, has been granted Orphan Drug Status by the U.S. Food and Drug Administration (FDA). Ubenimex, also…

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the…

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the treatment of pulmonary…